A multi-center, open-label evaluation of the safety of a new drug in the treatment of the signs and symptoms of benign prostatic hyperplasia

Trial Profile

A multi-center, open-label evaluation of the safety of a new drug in the treatment of the signs and symptoms of benign prostatic hyperplasia

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2010

At a glance

  • Drugs Silodosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Registrational
  • Sponsors Actavis Inc
  • Most Recent Events

    • 09 Dec 2009 Results published in Urology.
    • 01 Dec 2009 Results were reported in Urology.
    • 29 Sep 2008 Results presented at two regional meetings of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top